THEO-260

BIOLOGICAL3 trials

Sponsors

Theolytics Limited

Conditions

High grade serous or endometroid ovarian cancerOvarian Cancer

Phase 1

Trial of THEO-260 in Ovarian Cancer Patients

RecruitingNCT06618235

Theolytics LimitedOvarian Cancer

Start: 2024-09-24End: 2028-06-01Target: 44Updated: 2026-04-14

A Phase Ib/ IIa, open-label, dose finding, safety, tolerability and exploratory study of THEO-260 in patients with high grade serous or endometrioid ovarian cancer

RecruitingCTIS2024-511236-27-00

Theolytics LimitedHigh grade serous or endometroid ovarian cancer

Start: 2025-11-12Target: 5Updated: 2025-09-25

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

RecruitingNCT07211659

Theolytics LimitedOvarian Cancer

Start: 2026-02-13End: 2027-09-01Target: 18Updated: 2026-04-22

Related Papers

A phase I, open-label, dose-finding, safety, tolerability, and exploratory trial of intraperitoneal THEO-260 in patients with high-grade serous or endometrioid ovarian cancer.

Journal of Clinical Oncology2026-05-28